- Stocks
- Healthcare
- NASDAQ: SRPT

Price (delayed)

$71.38

Market cap

$5.67B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.11

Enterprise value

$5.24B

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going

SRPT's gross profit is up by 47% year-on-year and by 9% since the previous quarter

The revenue rose by 42% YoY and by 9% QoQ

Sarepta Therapeutics's quick ratio has increased by 7% YoY but it has decreased by 4.3% from the previous quarter

SRPT's debt is up by 47% year-on-year and by 40% since the previous quarter

The company's equity fell by 15% QoQ and by 7% YoY

What are the main financial stats of SRPT

Market
Valuations
Earnings

Shares outstanding

79.42M

Market cap

$5.67B

Enterprise value

$5.24B

Price to earnings (P/E)

N/A

Price to book (P/B)

7.39

Price to sales (P/S)

10.3

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

9.7

Revenue

$540.1M

EBIT

-$553.07M

EBITDA

-$513.33M

Free cash flow

$25.26M

Per share
Balance sheet
Liquidity

EPS

-$7.11

Free cash flow per share

$0.32

Book value per share

$9.65

Revenue per share

$6.93

TBVPS

$38.11

Total assets

$2.98B

Total liabilities

$2.22B

Debt

$1.07B

Equity

$761.76M

Working capital

$2.07B

Debt to equity

1.41

Current ratio

5.97

Quick ratio

4.9

Net debt/EBITDA

0.84

Margins
Efficiency
Dividend

EBITDA margin

-95%

Gross margin

88.3%

Net margin

-102.6%

Operating margin

-104.5%

Return on assets

-19.1%

Return on equity

-57.7%

Return on invested capital

-31.3%

Return on capital employed

-21.5%

Return on sales

-102.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Sarepta Therapeutics stock price performed over time

Intraday

0%

1 week

-0.58%

1 month

-9.16%

1 year

-38.1%

YTD

-58.13%

QTD

-4.23%

How have Sarepta Therapeutics's revenue and profit performed over time

Revenue

$540.1M

Gross profit

$476.72M

Operating income

-$564.16M

Net income

-$554.13M

Gross margin

88.3%

Net margin

-102.6%

SRPT's gross profit is up by 47% year-on-year and by 9% since the previous quarter

SRPT's net margin is up by 45% year-on-year and by 15% since the previous quarter

SRPT's operating margin is up by 44% YoY and by 17% from the previous quarter

The revenue rose by 42% YoY and by 9% QoQ

What is Sarepta Therapeutics's growth rate over time

What is Sarepta Therapeutics stock price valuation

P/E

N/A

P/B

7.39

P/S

10.3

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

9.7

The EPS has grown by 27% YoY and by 9% from the previous quarter

SRPT's P/B is 39% below its last 4 quarters average of 12.2 and 13% below its 5-year quarterly average of 8.5

The company's equity fell by 15% QoQ and by 7% YoY

The P/S is 95% less than the 5-year quarterly average of 199.2 and 56% less than the last 4 quarters average of 23.3

The revenue rose by 42% YoY and by 9% QoQ

How efficient is Sarepta Therapeutics business performance

The ROA has soared by 52% YoY and by 17% from the previous quarter

The ROS has grown by 45% YoY and by 15% from the previous quarter

Sarepta Therapeutics's ROIC has increased by 40% YoY and by 17% from the previous quarter

The return on equity is up by 14% year-on-year and by 6% since the previous quarter

What is SRPT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for SRPT.

How did Sarepta Therapeutics financials performed over time

The total assets is 34% more than the total liabilities

SRPT's total liabilities has soared by 121% YoY and by 18% from the previous quarter

The total assets has soared by 64% YoY and by 7% from the previous quarter

SRPT's debt is 41% greater than its equity

The debt to equity has surged by 64% since the previous quarter and by 58% year-on-year

SRPT's debt is up by 47% year-on-year and by 40% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.